Notch signaling in human development and disease

Seminars in Cell and Developmental Biology

Volumn 23, Issue 4, 2012, Pages 450-457

  Penton, Andrea L ^a   Leonard, Laura D ^a   Spinner, Nancy B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alagille syndrome; Cardiac disease; Hajdu Cheney; Notch signaling; Spondylocostal dysostosis

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CRE RECOMBINASE; CYTOKERATIN; JAGGED1; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR;

ALAGILLE SYNDROME; AORTA COARCTATION; AORTA VALVE STENOSIS; AUTOSOMAL RECESSIVE DISORDER; BILE DUCT; CADASIL; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL MORPHOLOGY; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; FRAMESHIFT MUTATION; GENETIC VARIABILITY; HAJDU CHENEY SYNDROME; HUMAN; INHERITANCE; JARCHO LEVIN SYNDROME; KIDNEY CYST; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEGATIVE FEEDBACK; NEURAL CREST CELL; NONHUMAN; NONSENSE MUTATION; ORGANOGENESIS; OSTEOPOROSIS; PHENOTYPE; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84861969458     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.01.010     Document Type: Review

References (77)

1. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66(4):649-661.
2. Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383(6602):707-710.
3. Li L., Krantz I.D., Deng Y., Genin A., Banta A.B., Collins C.C., et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997, 16(3):243-251.
4. Alagille D., Borde J., Habib E.C., Thomassin N. Surgical attempts in atresia of the intrahepatic bile ducts with permeable extrahepatic bile duct. Study of 14 cases in children. Arch Fr Pediatr 1969, 26(1):51-71.
5. Riely C.A., Cotlier E., Jensen P.S., Klatskin G. Arteriohepatic dysplasia: a benign syndrome of intrahepatic cholestasis with multiple organ involvement. Ann Intern Med 1979, 91(4):520-527.
6. Watson G.H., Miller V. Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child 1973, 48(6):459-466.
7. Alagille D., Estrada A., Hadchouel M., Gautier M., Odievre M., Dommergues J.P. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987, 110(2):195-200.
8. Crosnier C., Driancourt C., Raynaud N., Dhorne-Pollet S., Pollet N., Bernard O., et al. Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. Gastroenterology 1999, 116(5):1141-1148.
9. Morrissette J.D., Colliton R.P., Spinner N.B. Defective intracellular transport and processing of JAG1 missense mutations in Alagille syndrome. Hum Mol Genet 2001, 10(4):405-413.
10. Bauer R.C., Laney A.O., Smith R., Gerfen J., Morrissette J.J., Woyciechowski S., et al. Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat 2010, 31(5):594-601.
11. Lu F., Morrissette J.J., Spinner N.B. Conditional JAG1 mutation shows the developing heart is more sensitive than developing liver to JAG1 dosage. Am J Hum Genet 2003, 72(4):1065-1070.
12. Kamath B.M., Bauer R.C., Loomes K.M., Chao G., Gerfen J., Hutchinson A., et al. NOTCH2 mutations in Alagille syndrome. J Med Genet 2011.
13. Guegan K., Stals K., Day M., Turnpenny P., Ellard S. JAG1 mutations are found in approximately one third of patients presenting with only one or two clinical features of Alagille syndrome. Clin Genet 2011.
14. Kamath B.M., Bason L., Piccoli D.A., Krantz I.D., Spinner N.B. Consequences of JAG1 mutations. J Med Genet 2003, 40(12):891-895.
15. Hadchouel M., Hugon R.N., Gautier M. Reduced ratio of portal tracts to paucity of intrahepatic bile ducts. Arch Pathol Lab Med 1978, 102(8):402.
16. Emerick K.M., Rand E.B., Goldmuntz E., Krantz I.D., Spinner N.B., Piccoli D.A. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999, 29(3):822-829.
17. Lorent K., Yeo S.Y., Oda T., Chandrasekharappa S., Chitnis A., Matthews R.P., et al. Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development and generates multi-organ defects compatible with an Alagille syndrome phenocopy. Development 2004, 131(22):5753-5766.
18. Vrijens, Thys K., De Jeu S., Postnov M.T., Pfister A.A., Cox M., et al. A Jag1 vestibular mouse mutant, displays characteristics of Alagille syndrome. Neurobiol Dis 2006, 24(1):28-40.
19. McCright B., Lozier J., Gridley T. Generation of new Notch2 mutant alleles. Genesis 2006, 44(1):29-33.
20. Xue Y., Gao X., Lindsell C.E., Norton C.R., Chang B., Hicks C., et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 1999, 8(5):723-730.
21. McCright B., Lozier J., Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 2002, 129(4):1075-1082.
22. Fernandez-Valdivia R., Takeuchi H., Samarghandi A., Lopez M., Leonardi J., Haltiwanger R.S., et al. Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development 2011, 138(10):1925-1934.
23. Ryan M.J., Bales C., Nelson A., Gonzalez D.M., Underkoffler L., Segalov M., et al. Bile duct proliferation in Jag1/fringe heterozygous mice identifies candidate modifiers of the Alagille syndrome hepatic phenotype. Hepatology 2008, 48(6):1989-1997.
24. Hofmann J.J., Zovein A.C., Koh H., Radtke F., Weinmaster G., Iruela-Arispe M.L. Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development 2010, 137(23):4061-4072.
25. Zong Y., Panikkar A., Xu J., Antoniou A., Raynaud P., Lemaigre F., et al. Notch signaling controls liver development by regulating biliary differentiation. Development 2009, 136(10):1727-1739.
26. Raynaud P., Carpentier R., Antoniou A., Lemaigre F.P. Biliary differentiation and bile duct morphogenesis in development and disease. Int J Biochem Cell Bio 2011, 43(2):245-256.
27. Loomes K.M., Russo P., Ryan M., Nelson A., Underkoffler L., Glover C., et al. Bile duct proliferation in liver-specific Jag1 conditional knockout mice: effects of gene dosage. Hepatology 2007, 45(2):323-330.
28. Geisler F., Nagl F., Mazur P.K., Lee M., Zimber-Strobl U., Strobl L.J., et al. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 2008, 48(2):607-616.
29. Kodama Y., Hijikata M., Kageyama R., Shimotohno K., Chiba T. The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology 2004, 127(6):1775-1786.
30. Deutsch G.H., Sokol R.J., Stathos T.H., Knisely A.S. Proliferation to paucity: evolution of bile duct abnormalities in a case of Alagille syndrome. Pediatr Dev Pathol 2001, 4(6):559-563.
31. Sparks E.E., Perrien D.S., Huppert K.A., Peterson T.E., Huppert S.S. Defects in hepatic Notch signaling result in disruption of the communicating intrahepatic bile duct network in mice. Dis Model Mech 2011, 4(3):359-367.
32. McElhinney D.B., Krantz I.D., Bason L., Piccoli D.A., Emerick K.M., Spinner N.B., et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002, 106(20):2567-2574.
33. MacGrogan D., Nus M., de la Pompa J.L. Notch signaling in cardiac development and disease. Curr Top Dev Biol 2010, 92:333-365.
34. Kamath B.M., Loomes K.M., Oakey R.J., Emerick K.E., Conversano T., Spinner N.B., et al. Facial features in Alagille syndrome: specific or cholestasis facies?. Am J Med Genet 2002, 112(2):163-170.
35. Humphreys R., Zheng W., Prince L.S., Qu X., Brown C., Loomes K., et al. Cranial neural crest ablation of Jagged1 recapitulates the craniofacial phenotype of Alagille syndrome patients. Hum Mol Genet 2011, 1-10. 10.1093/hmg/ddr575.
36. Kamath B.M., Podkameni G., Hutchinson A.L., Leonard L.D., Gerfen J., Krantz I.D., et al. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A 2011.
37. Jacquet A., Guiochon-Mantel A., Noel L.H., Sqalli T., Bedossa P., Hadchouel M., et al. Alagille syndrome in adult patients: it is never too late. Am J Kidney Dis 2007, 49(5):705-709.
38. Piscione T.D., Wu M.Y., Quaggin S.E. Expression of Hairy/Enhancer of Split genes, Hes1 and Hes5, during murine nephron morphogenesis. Gene Expr Patterns 2004, 4(6):707-711.
39. Cheng H.T., Kopan R. The role of Notch signaling in specification of podocyte and proximal tubules within the developing mouse kidney. Kidney Int 2005, 68(5):1951-1952.
40. Kamath B.M., Spinner N.B., Emerick K.M., Chudley A.E., Booth C., Piccoli D.A., et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004, 109(11):1354-1358.
41. Woolfenden A.R., Albers G.W., Steinberg G.K., Hahn J.S., Johnston D.C., Farrell K. Moyamoya syndrome in children with Alagille syndrome: additional evidence of a vasculopathy. Pediatrics 1999, 103(2):505-508.
42. Manderfield L.J., High F.A., Engelka K.A., Liu F., Li L., Rentschler S., et al. Notch activation of Jagged1 contributes to the assembly of the arterial wall. Circulation 2011.
43. Greenway S.C., Pereira A.C., Lin J.C., DePalma S.R., Israel S.J., Mesquita S.M., et al. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet 2009, 41(8):931-935.
44. Kola S., Koneti N.R., Golla J.P., Akka J., Gundimeda S.D., Mundluru H.P. Mutational analysis of JAG1 gene in non-syndromic tetralogy of Fallot children. Clin Chim Acta 2011, 412(23-24):2232-2236.
45. Le Caignec C., Lefevre M., Schott J.J., Chaventre A., Gayet M., Calais C., et al. Familial deafness, congenital heart defects, and posterior embryotoxon caused by cysteine substitution in the first epidermal-growth-factor-like domain of jagged 1. Am J Hum Genet 2002, 71(1):180-186.
46. Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R., King I.N., et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437(7056):270-274.
47. McKellar S.H., Tester D.J., Yagubyan M., Majumdar R., Ackerman M.J., Sundt T.M. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007, 134(2):290-296.
48. Riley M.F., McBride K.L., Cole S.E. NOTCH1 missense alleles associated with left ventricular outflow tract defects exhibit impaired receptor processing and defective EMT. Biochim Biophys Acta 2011, 1812(1):121-129.
49. Timmerman L.A., Grego-Bessa J., Raya A., Bertran E., Perez-Pomares J.M., Diez J., et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 2004, 18(1):99-115.
50. MacGrogan D., Luna-Zurita L., de la Pompa J.L. Notch signaling in cardiac valve development and disease. Birth Defects Res A Clin Mol Teratol 2011, 91(6):449-459.
51. Pourquie O. Vertebrate segmentation: from cyclic gene networks to scoliosis. Cell 2011, 145(5):650-663.
52. Dunwoodie S.L. The role of Notch in patterning the human vertebral column. Curr Opin Genet Dev 2009, 19(4):329-337.
53. Turnpenny P.D., Alman B., Cornier A.S., Giampietro P.F., Offiah A., Tassy O., et al. Abnormal vertebral segmentation and the notch signaling pathway in man. Dev Dyn 2007, 236(6):1456-1474.
54. Berdon W.E., Lampl B.S., Cornier A.S., Ramirez N., Turnpenny P.D., Vitale M.G., et al. Clinical and radiological distinction between spondylothoracic dysostosis (Lavy-Moseley syndrome) and spondylocostal dysostosis (Jarcho-Levin syndrome). Pediatr Radiol 2011, 41(3):384-388.
55. Bessho Y., Sakata R., Komatsu S., Shiota K., Yamada S., Kageyama R. Dynamic expression and essential functions of Hes7 in somite segmentation. Genes Dev 2001, 15(20):2642-2647.
56. Dunwoodie S.L., Clements M., Sparrow D.B., Sa X., Conlon R.A., Beddington R.S. Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene Dll3 are associated with disruption of the segmentation clock within the presomitic mesoderm. Development 2002, 129(7):1795-1806.
57. Evrard Y.A., Lun Y., Aulehla A., Gan L., Johnson R.L. Lunatic Fringe is an essential mediator of somite segmentation and patterning. Nature 1998, 394(6691):377-381.
58. Saga Y., Hata N., Koseki H., Taketo M.M. Mesp2: a novel mouse gene expressed in the presegmented mesoderm and essential for segmentation initiation. Genes Dev 1997, 11(14):1827-1839.
59. Bulman M.P., Kusumi K., Frayling T.M., McKeown C., Garrett C., Lander E.S., et al. Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nat Genet 2000, 24(4):438-441.
60. Turnpenny P.D., Whittock N., Duncan J., Dunwoodie S., Kusumi K., Ellard S. Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis. J Med Genet 2003, 40(5):333-339.
61. Ladi E., Nichols J.T., Ge W., Miyamoto A., Yao C., Yang L.T., et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol 2005, 170(6):983-992.
62. Chapman G., Sparrow D.B., Kremmer E., Dunwoodie S.L. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet 2010, 20(5):905-916.
63. Sparrow D.B., Chapman G., Wouters M.A., Whittock N.V., Ellard S., Fatkin D., et al. Mutation of the Lunatic Fringe gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. Am J Hum Genet 2006, 78(1):28-37.
64. Whittock N.V., Sparrow D.B., Wouters M.A., Sillence D., Ellard S., Dunwoodie S.L., et al. Mutated MESP2 causes spondylocostal dysostosis in humans. Am J Hum Genet 2004, 74(6):1249-1254.
65. Cornier A.S., Staehling-Hampton K., Delventhal K.M., Saga Y., Caubet J.F., Sasaki N., et al. Mutations in the MESP2 gene cause spondylothoracic dysostosis/Jarcho-Levin syndrome. Am J Hum Genet 2008, 82(6):1334-1341.
66. Kageyama R., Niwa Y., Shimojo H., Kobayashi T., Ohtsuka T. Ultradian oscillations in Notch signaling regulate dynamic biological events. Curr Top Dev Biol 2010, 92:311-331.
67. Sparrow D.B., Guillen-Navarro E., Fatkin D., Dunwoodie S.L. Mutation of Hairy-and-Enhancer-of-Split-7 in humans causes spondylocostal dysostosis. Hum Mol Genet 2008, 17(23):3761-3766.
68. Sparrow D.B., Sillence D., Wouters M.A., Turnpenny P.D., Dunwoodie S.L. Two novel missense mutations in Hairy-and-Enhancer-of-Split-7 in a family with spondylocostal dysostosis. Eur J Hum Genet 2010, 18(6):674-679.
69. Morimoto M., Takahashi Y., Endo M., Saga Y. The Mesp2 transcription factor establishes segmental borders by suppressing Notch activity. Nature 2005, 435(7040):354-359.
70. Sasaki N., Kiso M., Kitagawa M., Saga Y. The repression of Notch signaling occurs via the destabilization of mastermind-like 1 by Mesp2 and is essential for somitogenesis. Development 2011, 138(1):55-64.
71. Feller J., Schneider A., Schuster-Gossler K., Gossler A. Noncyclic Notch activity in the presomitic mesoderm demonstrates uncoupling of somite compartmentalization and boundary formation. Genes Dev 2008, 22(16):2166-2171.
72. Gray M.J., Kim C.A., Bertola D.R., Arantes P.R., Stewart H., Simpson M.A., et al. Serpentine fibula polycystic kidney syndrome is part of the phenotypic spectrum of Hajdu-Cheney syndrome. Eur J Hum Genet 2011, 20(1):122-124.
73. Isidor B., Le Merrer M., Exner G.U., Pichon O., Thierry G., Guiochon-Mantel A., et al. Serpentine fibula-polycystic kidney syndrome caused by truncating mutations in NOTCH2. Hum Mutat 2011, 32(11):1239-1242.
74. Simpson M.A., Irving M.D., Asilmaz E., Gray M.J., Dafou D., Elmslie F.V., et al. Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat Genet 2011, 43(4):303-305.
75. Lee S.Y., Kumano K., Nakazaki K., Sanada M., Matsumoto A., Yamamoto G., et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009, 100(5):920-926.
76. Chiang M.Y., Xu M.L., Histen G., Shestova O., Roy M., Nam Y., et al. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Mol Cell Biol 2006, 26(16):6261-6271.
77. Bales C.B., Kamath B.M., Munoz P.S., Nguyen A., Piccoli D.A., Spinner N.B., et al. Pathologic lower extremity fractures in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 2010, 51(1):66-70.